BRAF V600E mutation in metastatic colorectal cancer: Methods of detection and correlation with clinical and pathologic features

Cristin Roma, Anna Maria Rachiglio, Raffaella Pasquale, Francesca Fenizia, Alessia Iannaccone, Fabiana Tatangelo, Giuseppe Antinolfi, Lina Sabatino, Vittorio Colantuoni, Gerardo Botti, Nicola Normanno

Research output: Contribution to journalArticle

Abstract

The screening for BRAF V600E mutation is employed in clinical practice for its prognostic and potentially predictive role in patients with metastatic colorectal carcinoma (mCRC). Little information is available on the sensitivity and specificity of the testing methods to detect this mutation in CRC. By using serial dilution of BRAF mutant DNA with wild type DNA, we found that the sensitivity of allelic discrimination-Real Time PCR was higher than PCR-Sequencing (10% vs 20%). In agreement, the Real Time PCR assay displayed increased analytical sensitivity in detecting the BRAF V600E mutation as compared with PCR-Sequencing in a cohort of 510 consecutive CRCs (21 vs 16 cases). Targeted resequencing demonstrated that all cases negative by PCR-Sequencing had an allelic frequency of the BRAF mutation <20%, thus suggesting tumor heterogeneity. The association of BRAF mutations with clinical and pathological features was assessed next in a cohort of 840 KRAS exon 2 wild type CRC patients screened with the Real Time PCR assay. The BRAF V600E mutation frequency in this cohort was 7.8% that increased to 33.4% in females over 70 y of age with right-sided tumor location. BRAF mutations were also detected in 4.4% of male patients with left-sided tumors and aged <70 y. Fourteen of 61 (22.9%) BRAF V600E mutation bearing patients exhibited microsatellite instability (MSI) as assessed by T17 mononucleotide sequence within intron 8 of HSP110. Our study indicates that Real Time PCR-based assays are more sensitive than PCR-Sequencing to detect the BRAF V600E mutation in CRC and that BRAF mutations screening should not be restricted to selected patients on the basis of the clinical-pathological characteristics.

Original languageEnglish
Pages (from-to)840-848
Number of pages9
JournalCancer Biology and Therapy
Volume17
Issue number8
DOIs
Publication statusPublished - Aug 2 2016

Fingerprint

Colorectal Neoplasms
Mutation
Real-Time Polymerase Chain Reaction
Polymerase Chain Reaction
Mutation Rate
Neoplasms
Microsatellite Instability
DNA
Introns
Exons
Sensitivity and Specificity

Keywords

  • BRAF mutations
  • colorectal cancer
  • microsatellite instability
  • molecular diagnostics
  • PCR-Sequencing
  • Real Time PCR
  • tumor heterogeneity

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Cite this

BRAF V600E mutation in metastatic colorectal cancer : Methods of detection and correlation with clinical and pathologic features. / Roma, Cristin; Rachiglio, Anna Maria; Pasquale, Raffaella; Fenizia, Francesca; Iannaccone, Alessia; Tatangelo, Fabiana; Antinolfi, Giuseppe; Sabatino, Lina; Colantuoni, Vittorio; Botti, Gerardo; Normanno, Nicola.

In: Cancer Biology and Therapy, Vol. 17, No. 8, 02.08.2016, p. 840-848.

Research output: Contribution to journalArticle

Roma, Cristin ; Rachiglio, Anna Maria ; Pasquale, Raffaella ; Fenizia, Francesca ; Iannaccone, Alessia ; Tatangelo, Fabiana ; Antinolfi, Giuseppe ; Sabatino, Lina ; Colantuoni, Vittorio ; Botti, Gerardo ; Normanno, Nicola. / BRAF V600E mutation in metastatic colorectal cancer : Methods of detection and correlation with clinical and pathologic features. In: Cancer Biology and Therapy. 2016 ; Vol. 17, No. 8. pp. 840-848.
@article{b6764ce378534bb59c9f55c0bd0feeb7,
title = "BRAF V600E mutation in metastatic colorectal cancer: Methods of detection and correlation with clinical and pathologic features",
abstract = "The screening for BRAF V600E mutation is employed in clinical practice for its prognostic and potentially predictive role in patients with metastatic colorectal carcinoma (mCRC). Little information is available on the sensitivity and specificity of the testing methods to detect this mutation in CRC. By using serial dilution of BRAF mutant DNA with wild type DNA, we found that the sensitivity of allelic discrimination-Real Time PCR was higher than PCR-Sequencing (10{\%} vs 20{\%}). In agreement, the Real Time PCR assay displayed increased analytical sensitivity in detecting the BRAF V600E mutation as compared with PCR-Sequencing in a cohort of 510 consecutive CRCs (21 vs 16 cases). Targeted resequencing demonstrated that all cases negative by PCR-Sequencing had an allelic frequency of the BRAF mutation <20{\%}, thus suggesting tumor heterogeneity. The association of BRAF mutations with clinical and pathological features was assessed next in a cohort of 840 KRAS exon 2 wild type CRC patients screened with the Real Time PCR assay. The BRAF V600E mutation frequency in this cohort was 7.8{\%} that increased to 33.4{\%} in females over 70 y of age with right-sided tumor location. BRAF mutations were also detected in 4.4{\%} of male patients with left-sided tumors and aged <70 y. Fourteen of 61 (22.9{\%}) BRAF V600E mutation bearing patients exhibited microsatellite instability (MSI) as assessed by T17 mononucleotide sequence within intron 8 of HSP110. Our study indicates that Real Time PCR-based assays are more sensitive than PCR-Sequencing to detect the BRAF V600E mutation in CRC and that BRAF mutations screening should not be restricted to selected patients on the basis of the clinical-pathological characteristics.",
keywords = "BRAF mutations, colorectal cancer, microsatellite instability, molecular diagnostics, PCR-Sequencing, Real Time PCR, tumor heterogeneity",
author = "Cristin Roma and Rachiglio, {Anna Maria} and Raffaella Pasquale and Francesca Fenizia and Alessia Iannaccone and Fabiana Tatangelo and Giuseppe Antinolfi and Lina Sabatino and Vittorio Colantuoni and Gerardo Botti and Nicola Normanno",
year = "2016",
month = "8",
day = "2",
doi = "10.1080/15384047.2016.1195048",
language = "English",
volume = "17",
pages = "840--848",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "8",

}

TY - JOUR

T1 - BRAF V600E mutation in metastatic colorectal cancer

T2 - Methods of detection and correlation with clinical and pathologic features

AU - Roma, Cristin

AU - Rachiglio, Anna Maria

AU - Pasquale, Raffaella

AU - Fenizia, Francesca

AU - Iannaccone, Alessia

AU - Tatangelo, Fabiana

AU - Antinolfi, Giuseppe

AU - Sabatino, Lina

AU - Colantuoni, Vittorio

AU - Botti, Gerardo

AU - Normanno, Nicola

PY - 2016/8/2

Y1 - 2016/8/2

N2 - The screening for BRAF V600E mutation is employed in clinical practice for its prognostic and potentially predictive role in patients with metastatic colorectal carcinoma (mCRC). Little information is available on the sensitivity and specificity of the testing methods to detect this mutation in CRC. By using serial dilution of BRAF mutant DNA with wild type DNA, we found that the sensitivity of allelic discrimination-Real Time PCR was higher than PCR-Sequencing (10% vs 20%). In agreement, the Real Time PCR assay displayed increased analytical sensitivity in detecting the BRAF V600E mutation as compared with PCR-Sequencing in a cohort of 510 consecutive CRCs (21 vs 16 cases). Targeted resequencing demonstrated that all cases negative by PCR-Sequencing had an allelic frequency of the BRAF mutation <20%, thus suggesting tumor heterogeneity. The association of BRAF mutations with clinical and pathological features was assessed next in a cohort of 840 KRAS exon 2 wild type CRC patients screened with the Real Time PCR assay. The BRAF V600E mutation frequency in this cohort was 7.8% that increased to 33.4% in females over 70 y of age with right-sided tumor location. BRAF mutations were also detected in 4.4% of male patients with left-sided tumors and aged <70 y. Fourteen of 61 (22.9%) BRAF V600E mutation bearing patients exhibited microsatellite instability (MSI) as assessed by T17 mononucleotide sequence within intron 8 of HSP110. Our study indicates that Real Time PCR-based assays are more sensitive than PCR-Sequencing to detect the BRAF V600E mutation in CRC and that BRAF mutations screening should not be restricted to selected patients on the basis of the clinical-pathological characteristics.

AB - The screening for BRAF V600E mutation is employed in clinical practice for its prognostic and potentially predictive role in patients with metastatic colorectal carcinoma (mCRC). Little information is available on the sensitivity and specificity of the testing methods to detect this mutation in CRC. By using serial dilution of BRAF mutant DNA with wild type DNA, we found that the sensitivity of allelic discrimination-Real Time PCR was higher than PCR-Sequencing (10% vs 20%). In agreement, the Real Time PCR assay displayed increased analytical sensitivity in detecting the BRAF V600E mutation as compared with PCR-Sequencing in a cohort of 510 consecutive CRCs (21 vs 16 cases). Targeted resequencing demonstrated that all cases negative by PCR-Sequencing had an allelic frequency of the BRAF mutation <20%, thus suggesting tumor heterogeneity. The association of BRAF mutations with clinical and pathological features was assessed next in a cohort of 840 KRAS exon 2 wild type CRC patients screened with the Real Time PCR assay. The BRAF V600E mutation frequency in this cohort was 7.8% that increased to 33.4% in females over 70 y of age with right-sided tumor location. BRAF mutations were also detected in 4.4% of male patients with left-sided tumors and aged <70 y. Fourteen of 61 (22.9%) BRAF V600E mutation bearing patients exhibited microsatellite instability (MSI) as assessed by T17 mononucleotide sequence within intron 8 of HSP110. Our study indicates that Real Time PCR-based assays are more sensitive than PCR-Sequencing to detect the BRAF V600E mutation in CRC and that BRAF mutations screening should not be restricted to selected patients on the basis of the clinical-pathological characteristics.

KW - BRAF mutations

KW - colorectal cancer

KW - microsatellite instability

KW - molecular diagnostics

KW - PCR-Sequencing

KW - Real Time PCR

KW - tumor heterogeneity

UR - http://www.scopus.com/inward/record.url?scp=84984839715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984839715&partnerID=8YFLogxK

U2 - 10.1080/15384047.2016.1195048

DO - 10.1080/15384047.2016.1195048

M3 - Article

AN - SCOPUS:84984839715

VL - 17

SP - 840

EP - 848

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 8

ER -